Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial.
We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval, including the shift in treatment strategies, the importance of ctDNA monitoring, and the potential benefits for patient quality of life.
Key topics covered in this episode:
Overview of the SERENA-6 trial and its findings
The role of ESR1 mutations in treatment resistance
The efficacy and safety profile of camizestrant
Practical insights on integrating next-generation sequencing (NGS) testing into clinical practice
Management of side effects, including bradycardia and QT prolongation
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information.
Podden och tillhörande omslagsbild på den här sidan tillhör
Oncology Brothers. Innehållet i podden är skapat av Oncology Brothers och inte av,
eller tillsammans med, Poddtoppen.
